Dominique STOPPA-LYONNET
Head of genetics department
Institut Curie & Paris Cité University
France
Current situation :
Head of the Genetics Department at Institut Curie and Professor of Medical Genetics at the University of Paris Cité
Main affiliations:
Founding member of the Genetics and Cancer Group (Unicancer); CCNE from 2005 to 2013; ABM Medical and Scientific Council from 2005 to 2015; President of the Scientific Council of AT-Europe; Scientific Council of the Fanconi Disease Association; Sponsorship Committee of the Assistance Program for the Emergency Reception of Scientists in Emergency, PAUSE; GRAM, Reflection Group with Patient Associations, INSERM; President of the Scientific and Ethics Council of SeqOIA-PFMG2015; Chair of the Institutional Ethics Commission of the Institut Curie; INCa Deontology and Ethics Committee; Councilor of Paris from 2014 to 2020.
Awards and Recognition :
René Fauvert Prize from the Hospitals of Paris, 1990; Prix de la Ligue contre le Cancer des Yvelines, 1999; Prize of the National Academy of Surgery, 2002; “Breast Cancer Month” Foundation Prize with Olga Sinilnikova and Sylvie Mazoyer, 2004; Knight of the Legion of Honor, promotion of July 14, 2006; Henry and Mary-Jeanne Mitjaville Prize, Academy of Medicine, 2007; Jean Bernard Communication Prize, Foundation for Medical Research, 2014
Dominique Stoppa-Lyonnet's medical and scientific work focuses mainly on cancer predisposition genes and in particular on breast and ovarian cancer predisposition genes. Her overall vision has led her to understand as much the molecular diagnosis of a predisposition, the definition of the care of people at high risk as the identification of risk modifying factors. With the Institut Curie, the Institut Gustave Roussy and the APHP, Dominique Stoppa-Lyonnet was a spearhead between 2001 and 2004 against the opposition to European patents relating to the BRCA1 and BRCA2 genes. In 2007, she coordinated for the INCa and the ABM a report on the place of prenatal diagnosis, medical termination and pregnancy and preimplantation diagnosis in genetic predisposition to cancer. She was co-rapporteur of two CCNE opinions on prenatal and preimplantation diagnostics. In 2021, she co-coordinated for the National League against Cancer and Unicancer an advocacy for the Minister of Health for access to genetic testing in oncology.